Company Description
NeuroPace, Inc. operates as a medical device company in the United States.
The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy.
It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures.
NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Apr 22, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 171 |
| CEO | Joel D. Becker |
Contact Details
Address: 455 N. Bernardo Avenue Mountain View, California 94043 United States | |
| Phone | (650) 237-2700 |
| Website | neuropace.com |
Stock Details
| Ticker Symbol | NPCE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001528287 |
| CUSIP Number | 641288105 |
| ISIN Number | US6412881053 |
| Employer ID | 22-3550230 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martha J. Morrell | Chief Medical Officer |
| Joel D. Becker | Chief Executive Officer, President and Director |
| Rebecca L. Kuhn | Chief Financial Officer, Vice President of Finance and Administration and Assistant Secretary |
| Kelley Nicholas | Vice President of Sales |
| Irene Thomas | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 15, 2024 | 144 | Filing |
| Mar 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2024 | 10-K | Annual Report |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |